Nucleic Acid Targets and Therapeutics (I-W5)

Chairs: Sidney Altman
  Valentin Vlassov

July 10, 2013

17.00 – 17.40

Mike Gait    MRC Laboratory of Molecular Biology, UK

Peptide conjugates of morpholino oligonucleotides (PMO) for exon skipping in Duchenne muscular dystrophy

17.40 – 18.05

Georg Sczakiel   University of Lubeck, Germany

Intracellular delivery of siRNAs

18.05 – 18.30

Jorgen Kjems   Interdisciplinary Nanoscience Center, France


18.30 – 18.55

Jian-Sheng Sun   DNA Therapeutics, France

The "Dbait": A new class of DNA repair inhibitors, from concept to clinic

18.55 – 19.10

Ulrich Hahn   Hamburg University, MIN-Faculty, Chemistry Department, Institute for Biochemistry and Molecular Biology, Germany

Multifunctional interleukin-6 receptor specific DNA and RNA aptamers

19.10 – 19.25

Giedrius Gasiunas   Institute of Biotechnology, Vilnius University, Vilnius, Lithuania

Cas9 – a programmable RNA-guided DNA endonuclease from the bacterial adaptive immune system

19.25 – 19.40

Vildan Bozok Cetintas   Department of Medical Biology, Ege University School of Medicine, Izmir, Turkey

Inhibition of STAT3 expression via chemically modified siRNA’s enhances the effects of cisplatin in the parental and resistant Calu1 non-small cell lung cancer cells